CA2163618A1 - Additifs pour des milieux de culture destines a des bioreacteurs - Google Patents
Additifs pour des milieux de culture destines a des bioreacteursInfo
- Publication number
- CA2163618A1 CA2163618A1 CA002163618A CA2163618A CA2163618A1 CA 2163618 A1 CA2163618 A1 CA 2163618A1 CA 002163618 A CA002163618 A CA 002163618A CA 2163618 A CA2163618 A CA 2163618A CA 2163618 A1 CA2163618 A1 CA 2163618A1
- Authority
- CA
- Canada
- Prior art keywords
- media
- run
- bioreactor
- cell culture
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 9
- 239000000654 additive Substances 0.000 title claims description 26
- 238000004113 cell culture Methods 0.000 claims abstract description 41
- 239000012510 hollow fiber Substances 0.000 claims abstract description 38
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 36
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 34
- 239000001301 oxygen Substances 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 68
- 238000004519 manufacturing process Methods 0.000 claims description 40
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 36
- 239000002054 inoculum Substances 0.000 claims description 21
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 20
- 241000283690 Bos taurus Species 0.000 claims description 17
- 230000035899 viability Effects 0.000 claims description 14
- 230000013595 glycosylation Effects 0.000 claims description 11
- 238000006206 glycosylation reaction Methods 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 230000003134 recirculating effect Effects 0.000 claims description 9
- 239000006143 cell culture medium Substances 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 7
- 235000015097 nutrients Nutrition 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 230000008901 benefit Effects 0.000 claims description 5
- 230000003833 cell viability Effects 0.000 claims description 5
- 229960000074 biopharmaceutical Drugs 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 108010061951 Methemoglobin Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000013028 medium composition Substances 0.000 claims description 2
- 238000006213 oxygenation reaction Methods 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims 7
- 230000001276 controlling effect Effects 0.000 claims 3
- 238000012856 packing Methods 0.000 claims 2
- 241000206602 Eukaryota Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 76
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 52
- 239000012091 fetal bovine serum Substances 0.000 description 52
- 229930182555 Penicillin Natural products 0.000 description 40
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 40
- 229940049954 penicillin Drugs 0.000 description 40
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 39
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 38
- 229960005322 streptomycin Drugs 0.000 description 38
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 34
- 238000003306 harvesting Methods 0.000 description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 17
- 239000008103 glucose Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 239000000835 fiber Substances 0.000 description 13
- 210000004408 hybridoma Anatomy 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 10
- 239000003633 blood substitute Substances 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 102000004237 Decorin Human genes 0.000 description 7
- 108090000738 Decorin Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000007640 basal medium Substances 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- -1 polyethylene Polymers 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 6
- 230000004190 glucose uptake Effects 0.000 description 6
- 230000016784 immunoglobulin production Effects 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000000951 immunodiffusion Effects 0.000 description 4
- 230000037447 lactate metabolism Effects 0.000 description 4
- 230000001706 oxygenating effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940109615 oxy 10 Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- 108010031004 PEG-hemoglobin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 108010032719 erythrogen Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
On décrit un milieu de culture destiné à des bioréacteurs à fibres creuses, qui contient de l'hémoglobine stabilisée ou une émulsion d'un composé perfluoré. Le milieu de culture favorise l'absorption et l'utilisation de l'oxygène. L'efficacité du bioréacteur est améliorée. On obtient ainsi de nouvelles configurations de systèmes, de nouveaux équipements et de nouveaux procédés de culture de cellules faisant appel à des fibres creuses et à des réacteurs agités.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1994/003613 WO1995027040A1 (fr) | 1994-04-01 | 1994-04-01 | Additifs pour un milieu de culture destine a des bioreacteurs a fibres creuses |
| WOUS94/03613 | 1994-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2163618A1 true CA2163618A1 (fr) | 1995-10-12 |
Family
ID=22242416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002163618A Abandoned CA2163618A1 (fr) | 1994-04-01 | 1994-07-26 | Additifs pour des milieux de culture destines a des bioreacteurs |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0711339A1 (fr) |
| JP (1) | JPH08511173A (fr) |
| AU (2) | AU6766994A (fr) |
| CA (1) | CA2163618A1 (fr) |
| NO (1) | NO954854D0 (fr) |
| WO (2) | WO1995027040A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6255109B1 (en) * | 1998-06-24 | 2001-07-03 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Nitric oxide-scavenging system for culturing oocytes, embryos, or other cells |
| GB9915413D0 (en) | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Propagation method |
| AUPQ319199A0 (en) * | 1999-09-30 | 1999-10-28 | Unisearch Limited | Method and apparatus for culturing cells |
| AU781265B2 (en) * | 1999-09-30 | 2005-05-12 | Unisearch Limited | Method and apparatus for culturing cells |
| EP1317526B1 (fr) * | 2000-09-13 | 2008-05-21 | Csir | Dispositif bioreacteur |
| DE10136912A1 (de) * | 2001-07-30 | 2003-02-20 | Wolfgang Fege | Verfahren zur Sauerstoffversorgung von Mikroorganismenkulturen, Kulturen von tierischen oder menschlichen Körperzellen und von Gewebekulturen, Organoiden, Organen |
| IN2013MN00600A (fr) | 2006-05-22 | 2015-06-12 | Univ California | |
| WO2010122080A1 (fr) * | 2009-04-23 | 2010-10-28 | Hemarina | Bioréacteur utilisant des molécules transporteuses d'oxygène |
| WO2010128159A1 (fr) * | 2009-05-07 | 2010-11-11 | Hemarina | Nouvelle hémoglobine et ses utilisations |
| WO2012048276A2 (fr) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Procédés et systèmes configurables pour la culture et la récolte de cellules dans un système de bioréacteur à fibres creuses |
| WO2016049421A1 (fr) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Alimentation programmée |
| CN109415696A (zh) | 2016-05-25 | 2019-03-01 | 泰尔茂比司特公司 | 细胞扩增 |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| EP3656841A1 (fr) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Expansion cellulaire |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593339A5 (fr) * | 1973-07-02 | 1977-11-30 | Monsanto Co | |
| US5223428A (en) * | 1982-12-14 | 1993-06-29 | Baxter International Inc. | Method for in vitro culture of mammalian cells |
| US5180676A (en) * | 1984-06-14 | 1993-01-19 | Teijin Limited | Method of cultivating animal or plant cells |
| EP0260627B1 (fr) * | 1986-09-19 | 1993-06-16 | Shimadzu Corporation | Incubateur sous pression |
| DE3871206D1 (de) * | 1987-03-24 | 1992-06-25 | Grace W R & Co | Basisnaehrmedium fuer eine zellkultur. |
| US5264555A (en) * | 1992-07-14 | 1993-11-23 | Enzon, Inc. | Process for hemoglobin extraction and purification |
-
1994
- 1994-04-01 AU AU67669/94A patent/AU6766994A/en not_active Abandoned
- 1994-04-01 WO PCT/US1994/003613 patent/WO1995027040A1/fr not_active Ceased
- 1994-07-26 AU AU73713/94A patent/AU7371394A/en not_active Abandoned
- 1994-07-26 CA CA002163618A patent/CA2163618A1/fr not_active Abandoned
- 1994-07-26 WO PCT/US1994/008295 patent/WO1995027041A1/fr not_active Ceased
- 1994-07-26 EP EP94922694A patent/EP0711339A1/fr not_active Withdrawn
- 1994-07-26 JP JP7525645A patent/JPH08511173A/ja active Pending
-
1995
- 1995-11-29 NO NO954854A patent/NO954854D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0711339A1 (fr) | 1996-05-15 |
| JPH08511173A (ja) | 1996-11-26 |
| WO1995027041A1 (fr) | 1995-10-12 |
| NO954854L (no) | 1995-11-29 |
| NO954854D0 (no) | 1995-11-29 |
| AU7371394A (en) | 1995-10-23 |
| AU6766994A (en) | 1995-10-23 |
| WO1995027040A1 (fr) | 1995-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2163618A1 (fr) | Additifs pour des milieux de culture destines a des bioreacteurs | |
| US5763266A (en) | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells | |
| EP0629236B1 (fr) | Methodes, compositions et dispositifs pour conserver et developper les cellules souches et/ou hematopoietiques humaines | |
| CA1107211A (fr) | Methode de multiplication et de conservation de cellules in vitro | |
| US8026096B1 (en) | In vivo active erythropoietin produced in insect cells | |
| EP2152856B1 (fr) | Milieux d'alimentation améliorés | |
| KR100998857B1 (ko) | 항-아밀로이드 베타 항체의 생산 | |
| KR101158447B1 (ko) | 폴리펩타이드의 생산 | |
| KR100196062B1 (ko) | 세포를 성장시키기 위한 방법, 조성물 및 장치 | |
| US20070122904A1 (en) | Method and apparatus for culturing cells | |
| US20020022270A1 (en) | Methods, compositions and devices for growing hematopoietics cells | |
| WO1992011355A1 (fr) | Procede de culture et de transformation de compositions contenant des cellules souches humaines | |
| JP2003510068A (ja) | 細胞を培養するための方法および装置 | |
| WO2005087915A2 (fr) | Utilisation d'ethanolamine pour renforcer la croissance cellulaire dans des systemes membranaires | |
| CN113862217B (zh) | 培养哺乳动物细胞的方法 | |
| EP0567738A2 (fr) | Commande des débits de perfusion dans la culture en continu de cellules animales dans un bioréacteur | |
| Capiaumont et al. | Bovine whey: a substitute for FBS in CHO-K1 cell cultures | |
| JPH10108673A (ja) | 中空糸型培養器を用いた動物細胞の培養方法 | |
| JP2500384B2 (ja) | 生理活性物質の製造法 | |
| Bond et al. | An Automated System for Hollow Fiber Cell Culture | |
| Schlaeger et al. | Improvement of mammalian cell fed-batch culture | |
| BOND et al. | Amicon Division, WR Grace & Co.-Conn. 72 Cherry Hill Drive Beverly, ΜΑ 01915 | |
| Brown et al. | Applications of the mass culturing technique (MCT) in the large scale growth of mammalian cells | |
| BOND et al. | Amicon Division, WR Grace & Co.-Conn. 72 Cherry Hill Drive | |
| Marx et al. | Cultivation of hybridomas, human cancer and human primary cells using the miniaturized hollow fibre bioreactor TECNOMOUSE® |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |